To include your compound in the COVID-19 Resource Center, submit it here.

HuMax-CD4: Phase I/II

In a 35-patient placebo controlled dose-escalating Phase I/II trial, HuMax-CD4 was

Read the full 115 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE